Replimune Group, Inc. - Common Stock (NQ:REPL)

14.82 -0.21 (-1.43%)

Streaming Delayed Price Updated: 11:33 AM EDT, Sep 8, 2026 Add to My Watchlist

Price and Volume

Volume	248,633
Open	14.90
Bid (Size)	14.79 (300)
Ask (Size)	14.82 (100)
Prev. Close	15.04
Today's Range	14.61 - 14.99
52wk Range	1.500 - 16.33
Shares Outstanding	46,772,263
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

Today 9:39 EDT

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

September 04, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

Performance

YTD	+66.6%	+66.6%
1 Month	+8.4%	+8.4%
3 Month	+65.3%	+65.3%
6 Month	+71.8%	+71.8%
1 Year	+145.4%	+145.4%

More News

Replimune to Present at the Cantor Global Healthcare Conference 2026

September 03, 2026

From Replimune, Inc.

Via GlobeNewswire

Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc.

September 02, 2026

From Robbins LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

September 01, 2026

From Pomerantz LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm

September 01, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

September 01, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

August 28, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 25, 2026

From Pomerantz LLP

Via GlobeNewswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

August 25, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm

August 21, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

August 21, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 21, 2026

From Pomerantz LLP

Via GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 19, 2026

From Replimune, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 18, 2026

From Pomerantz LLP

Via GlobeNewswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

August 18, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

Did You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPL

August 17, 2026

Via Newsfile

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 15, 2026

From Pomerantz LLP

Via GlobeNewswire

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

August 14, 2026

From Replimune, Inc.

Via GlobeNewswire

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL

August 13, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

August 13, 2026

From Levi & Korsinsky, LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 11, 2026

From Pomerantz LLP

Via GlobeNewswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

August 11, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

REPL INVESTOR ALERT: Securities Class Action Filed Against Replimune Group, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

August 10, 2026

From Kirby McInerney LLP

Via Business Wire

REPLIMUNE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm

August 10, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Frequently Asked Questions

Is Replimune Group, Inc. - Common Stock publicly traded?

Yes, Replimune Group, Inc. - Common Stock is publicly traded.

What exchange does Replimune Group, Inc. - Common Stock trade on?

Replimune Group, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Replimune Group, Inc. - Common Stock?

The ticker symbol for Replimune Group, Inc. - Common Stock is REPL on the Nasdaq Stock Market

What is the current price of Replimune Group, Inc. - Common Stock?

The current price of Replimune Group, Inc. - Common Stock is 14.82

When was Replimune Group, Inc. - Common Stock last traded?

The last trade of Replimune Group, Inc. - Common Stock was at 09/08/26 11:33 AM ET

What is the market capitalization of Replimune Group, Inc. - Common Stock?

The market capitalization of Replimune Group, Inc. - Common Stock is 693.40M

How many shares of Replimune Group, Inc. - Common Stock are outstanding?

Replimune Group, Inc. - Common Stock has 693M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.